Humanwell Healthcare Group Co Ltd (600079) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humanwell Healthcare Group Co Ltd (600079) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥829.91 Million ≈ $121.44 Million USD) by net assets (CN¥21.92 Billion ≈ $3.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Humanwell Healthcare Group Co Ltd worth for the company's overall valuation and market capitalisation.
Humanwell Healthcare Group Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Humanwell Healthcare Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Humanwell Healthcare Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humanwell Healthcare Group Co Ltd ranked by their cash flow conversion efficiency. Explore Humanwell Healthcare Group Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IONOS GROUP N
XETRA:IOS
|
0.148x |
|
Acerinox
MC:ACX
|
0.020x |
|
Jinneng Holding Shanxi Coal Industry Co Ltd
SHG:601001
|
0.030x |
|
AVIC Capital Co Ltd
SHG:600705
|
-0.321x |
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
-0.065x |
|
Poonawalla Fincorp Limited
NSE:POONAWALLA
|
0.085x |
|
UMICORE S.A UNSP.ADR 1/4
F:NVJ
|
N/A |
|
Cia de Distribucion Integral
MC:LOG
|
1.722x |
Annual Cash Flow Conversion Efficiency for Humanwell Healthcare Group Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Humanwell Healthcare Group Co Ltd from 1998 to 2025. View current stock price of Humanwell Healthcare Group Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥22.01 Billion ≈ $3.22 Billion |
CN¥2.52 Billion ≈ $368.57 Million |
0.114x | +9.43% |
| 2024-12-31 | CN¥20.69 Billion ≈ $3.03 Billion |
CN¥2.16 Billion ≈ $316.70 Million |
0.105x | +6.85% |
| 2023-12-31 | CN¥20.10 Billion ≈ $2.94 Billion |
CN¥1.97 Billion ≈ $287.87 Million |
0.098x | -28.06% |
| 2022-12-31 | CN¥17.94 Billion ≈ $2.63 Billion |
CN¥2.44 Billion ≈ $357.21 Million |
0.136x | -2.27% |
| 2021-12-31 | CN¥15.65 Billion ≈ $2.29 Billion |
CN¥2.18 Billion ≈ $318.83 Million |
0.139x | -9.08% |
| 2020-12-31 | CN¥12.99 Billion ≈ $1.90 Billion |
CN¥1.99 Billion ≈ $290.98 Million |
0.153x | +6.92% |
| 2019-12-31 | CN¥14.23 Billion ≈ $2.08 Billion |
CN¥2.04 Billion ≈ $298.20 Million |
0.143x | +243.92% |
| 2018-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
CN¥602.99 Million ≈ $88.24 Million |
0.042x | +1737.75% |
| 2017-12-31 | CN¥16.85 Billion ≈ $2.47 Billion |
CN¥38.17 Million ≈ $5.59 Million |
0.002x | -94.84% |
| 2016-12-31 | CN¥11.98 Billion ≈ $1.75 Billion |
CN¥526.48 Million ≈ $77.04 Million |
0.044x | +29.63% |
| 2015-12-31 | CN¥9.18 Billion ≈ $1.34 Billion |
CN¥311.22 Million ≈ $45.54 Million |
0.034x | -61.38% |
| 2014-12-31 | CN¥5.73 Billion ≈ $838.16 Million |
CN¥502.70 Million ≈ $73.56 Million |
0.088x | -10.50% |
| 2013-12-31 | CN¥5.08 Billion ≈ $743.41 Million |
CN¥498.22 Million ≈ $72.90 Million |
0.098x | +107.76% |
| 2012-12-31 | CN¥3.65 Billion ≈ $534.05 Million |
CN¥172.27 Million ≈ $25.21 Million |
0.047x | +57.24% |
| 2011-12-31 | CN¥3.14 Billion ≈ $459.33 Million |
CN¥94.23 Million ≈ $13.79 Million |
0.030x | -37.27% |
| 2010-12-31 | CN¥2.33 Billion ≈ $340.61 Million |
CN¥111.39 Million ≈ $16.30 Million |
0.048x | -35.56% |
| 2009-12-31 | CN¥2.08 Billion ≈ $304.49 Million |
CN¥154.51 Million ≈ $22.61 Million |
0.074x | +163.33% |
| 2008-12-31 | CN¥1.24 Billion ≈ $181.47 Million |
CN¥34.97 Million ≈ $5.12 Million |
0.028x | -40.22% |
| 2007-12-31 | CN¥1.17 Billion ≈ $170.79 Million |
CN¥55.05 Million ≈ $8.06 Million |
0.047x | -38.05% |
| 2006-12-31 | CN¥1.11 Billion ≈ $162.28 Million |
CN¥84.44 Million ≈ $12.36 Million |
0.076x | -53.95% |
| 2005-12-31 | CN¥768.89 Million ≈ $112.51 Million |
CN¥127.13 Million ≈ $18.60 Million |
0.165x | +69.79% |
| 2004-12-31 | CN¥724.52 Million ≈ $106.02 Million |
CN¥70.55 Million ≈ $10.32 Million |
0.097x | +37.37% |
| 2003-12-31 | CN¥681.54 Million ≈ $99.73 Million |
CN¥48.31 Million ≈ $7.07 Million |
0.071x | +169.37% |
| 2002-12-31 | CN¥682.71 Million ≈ $99.90 Million |
CN¥-69.77 Million ≈ $-10.21 Million |
-0.102x | -340.11% |
| 2001-12-31 | CN¥396.54 Million ≈ $58.03 Million |
CN¥16.88 Million ≈ $2.47 Million |
0.043x | -47.20% |
| 2000-12-31 | CN¥325.09 Million ≈ $47.57 Million |
CN¥26.20 Million ≈ $3.83 Million |
0.081x | +192.00% |
| 1999-12-31 | CN¥290.76 Million ≈ $42.55 Million |
CN¥-25.47 Million ≈ $-3.73 Million |
-0.088x | -747.02% |
| 1998-12-31 | CN¥201.81 Million ≈ $29.53 Million |
CN¥2.73 Million ≈ $399.87K |
0.014x | -- |
About Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pa… Read more